Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201206062 Principal Investigator: Mutch, David
Title: A Randomized, Double Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive Ovarian Cancer (Ver 1/11/12)
Phase: I/II Disease Site: Ovary
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
This study is being done to see how safe an investigational drug (LY2228820) is and how well it will work to help people with ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
 
More Information:
Internal Protocol Documents (requires Siteman administrative database password)